Cargando…

Covertly active and progressing neurochemical abnormalities in suppressed HIV infection

OBJECTIVE: To assess whether HIV-related brain injury is progressive in persons with suppressed HIV infection. METHODS: Seventy-three HIV+ virally suppressed men and 35 HIV− men, screened for psychiatric and alcohol/drug use disorders, underwent neuropsychological evaluation and proton magnetic reso...

Descripción completa

Detalles Bibliográficos
Autores principales: Cysique, Lucette A., Jugé, Lauriane, Gates, Thomas, Tobia, Michael, Moffat, Kirsten, Brew, Bruce J., Rae, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754644/
https://www.ncbi.nlm.nih.gov/pubmed/29312999
http://dx.doi.org/10.1212/NXI.0000000000000430
_version_ 1783290460065759232
author Cysique, Lucette A.
Jugé, Lauriane
Gates, Thomas
Tobia, Michael
Moffat, Kirsten
Brew, Bruce J.
Rae, Caroline
author_facet Cysique, Lucette A.
Jugé, Lauriane
Gates, Thomas
Tobia, Michael
Moffat, Kirsten
Brew, Bruce J.
Rae, Caroline
author_sort Cysique, Lucette A.
collection PubMed
description OBJECTIVE: To assess whether HIV-related brain injury is progressive in persons with suppressed HIV infection. METHODS: Seventy-three HIV+ virally suppressed men and 35 HIV− men, screened for psychiatric and alcohol/drug use disorders, underwent neuropsychological evaluation and proton magnetic resonance spectroscopy ((1)H-MRS) at baseline and after and 23 ± 5 months. (1)H-MRS included brain regions known to be vulnerable to HIV and aging: frontal white matter (FWM), posterior cingulate cortex (PCC), and caudate area (CA). Major brain metabolites such as creatine (Cr: marker of cellular energy), N-acetyl aspartate (NAA: marker of neuronal integrity), choline (marker of cellular membrane turnover), glutamate/glutamine (excitatory/inhibitory neurotransmitter), and myo-Inositol (mI: marker of neuroinflammation) were calculated with reference to water signal. Neurocognitive decline was corrected for practice effect and baseline HIV-associated neurocognitive disorder (HAND) status. RESULTS: Across the study period, 44% had intact cognition, 42% stable HAND (including the single case that improved), 10% progressing HAND, and 4% incident HAND. When analyzing the neurochemical data per neurocognitive trajectories, we found decreasing PCC Cr in all subgroups compared with controls (p < 0.002). In addition, relative to the HIV− group, stable HAND showed decreasing FWM Cr, incident HAND showed steep FWM Cr reduction, whereas progressing HAND had a sharply decreasing PCC NAA and reduced but stable CA NAA. When analyzing the neurochemical data at the group level (HIV+ vs HIV− groups), we found stable abnormal metabolite concentrations over the study period: decreased FWM and PCC Cr (both p < 0.001), decreased PCC NAA and CA NAA (both p < 0.05) and PCC mI increase (p < 0.05). HIV duration and historical HAND had modest effects on metabolite changes. CONCLUSIONS: Our study reveals covertly active or progressing HIV-related brain injury in the majority of this virally suppressed cohort, reflecting ongoing neuropathogenic processes that are only partially worsened by historical HAND and HIV duration. Longer-term studies will be important for determining the prognosis of these slowly evolving neurochemical abnormalities.
format Online
Article
Text
id pubmed-5754644
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-57546442018-01-08 Covertly active and progressing neurochemical abnormalities in suppressed HIV infection Cysique, Lucette A. Jugé, Lauriane Gates, Thomas Tobia, Michael Moffat, Kirsten Brew, Bruce J. Rae, Caroline Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To assess whether HIV-related brain injury is progressive in persons with suppressed HIV infection. METHODS: Seventy-three HIV+ virally suppressed men and 35 HIV− men, screened for psychiatric and alcohol/drug use disorders, underwent neuropsychological evaluation and proton magnetic resonance spectroscopy ((1)H-MRS) at baseline and after and 23 ± 5 months. (1)H-MRS included brain regions known to be vulnerable to HIV and aging: frontal white matter (FWM), posterior cingulate cortex (PCC), and caudate area (CA). Major brain metabolites such as creatine (Cr: marker of cellular energy), N-acetyl aspartate (NAA: marker of neuronal integrity), choline (marker of cellular membrane turnover), glutamate/glutamine (excitatory/inhibitory neurotransmitter), and myo-Inositol (mI: marker of neuroinflammation) were calculated with reference to water signal. Neurocognitive decline was corrected for practice effect and baseline HIV-associated neurocognitive disorder (HAND) status. RESULTS: Across the study period, 44% had intact cognition, 42% stable HAND (including the single case that improved), 10% progressing HAND, and 4% incident HAND. When analyzing the neurochemical data per neurocognitive trajectories, we found decreasing PCC Cr in all subgroups compared with controls (p < 0.002). In addition, relative to the HIV− group, stable HAND showed decreasing FWM Cr, incident HAND showed steep FWM Cr reduction, whereas progressing HAND had a sharply decreasing PCC NAA and reduced but stable CA NAA. When analyzing the neurochemical data at the group level (HIV+ vs HIV− groups), we found stable abnormal metabolite concentrations over the study period: decreased FWM and PCC Cr (both p < 0.001), decreased PCC NAA and CA NAA (both p < 0.05) and PCC mI increase (p < 0.05). HIV duration and historical HAND had modest effects on metabolite changes. CONCLUSIONS: Our study reveals covertly active or progressing HIV-related brain injury in the majority of this virally suppressed cohort, reflecting ongoing neuropathogenic processes that are only partially worsened by historical HAND and HIV duration. Longer-term studies will be important for determining the prognosis of these slowly evolving neurochemical abnormalities. Lippincott Williams & Wilkins 2018-01-03 /pmc/articles/PMC5754644/ /pubmed/29312999 http://dx.doi.org/10.1212/NXI.0000000000000430 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Cysique, Lucette A.
Jugé, Lauriane
Gates, Thomas
Tobia, Michael
Moffat, Kirsten
Brew, Bruce J.
Rae, Caroline
Covertly active and progressing neurochemical abnormalities in suppressed HIV infection
title Covertly active and progressing neurochemical abnormalities in suppressed HIV infection
title_full Covertly active and progressing neurochemical abnormalities in suppressed HIV infection
title_fullStr Covertly active and progressing neurochemical abnormalities in suppressed HIV infection
title_full_unstemmed Covertly active and progressing neurochemical abnormalities in suppressed HIV infection
title_short Covertly active and progressing neurochemical abnormalities in suppressed HIV infection
title_sort covertly active and progressing neurochemical abnormalities in suppressed hiv infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754644/
https://www.ncbi.nlm.nih.gov/pubmed/29312999
http://dx.doi.org/10.1212/NXI.0000000000000430
work_keys_str_mv AT cysiquelucettea covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection
AT jugelauriane covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection
AT gatesthomas covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection
AT tobiamichael covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection
AT moffatkirsten covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection
AT brewbrucej covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection
AT raecaroline covertlyactiveandprogressingneurochemicalabnormalitiesinsuppressedhivinfection